HR+, HER2-, ADVANCED BREAST CANCER
Clinical trials for HR+, HER2-, ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+, HER2-, ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+, HER2-, ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World look at cancer Drug's impact on Seniors' lives
Disease control OngoingThis study is observing how well a standard breast cancer drug combination works for patients aged 65 and older during their normal medical care in Russia. It aims to see how the treatment affects patients' quality of life, how long the cancer stays under control, and what side e…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Tracking Real-Life results: can this breast cancer drug combo buy more time?
Disease control OngoingThis study observes how well two different treatment approaches work for people with advanced HR+HER2- breast cancer in everyday Russian medical practice. It follows 376 patients who have already started treatment with either ribociclib plus hormone therapy or standard chemothera…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Study withdrawn before launch: what we could have learned about breast cancer treatments
Knowledge-focused TerminatedThis study aimed to collect real-world information about how well treatments work and what side effects people experience when managing advanced breast cancer. Researchers planned to follow adults with hormone-positive, HER2-negative advanced breast cancer during their routine me…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: SciClone Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC